DEF: Denali Capital Acquisition Corp. Seeks Shareholder Approval for Extension to Complete Business Combination

Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination from April 11, 2025, to December 11, 2025, to allow more time to finalize a deal.

Summary

• Denali Capital Acquisition Corp., a Cayman Islands exempted company, is seeking shareholder approval for an extension to complete an initial business combination.
• The company's extraordinary general meeting is scheduled for April 10, 2025, to vote on proposals to extend the deadline from April 11, 2025, to December 11, 2025.
• The extension requires an amendment to the company's amended and restated memorandum and articles of association.
• If approved, the Sponsor will deposit $0.02 per public share per month into the trust account for up to eight months.
• Shareholders can redeem their Class A ordinary shares for approximately $12.13 per share, based on the trust account balance as of the record date.
• If the extension is not approved, the company will liquidate and dissolve, with warrants expiring worthless.
• The company has entered into a merger agreement with Semnur Pharmaceuticals, Inc., but believes more time is needed to complete the business combination.
• Nasdaq will suspend trading of the company's securities and commence delisting proceedings on or about April 6, 2025, due to the company's failure to consummate a business combination within 36 months of effectiveness of its initial public offering registration statement.
• The company expects to receive a delisting determination letter from Nasdaq on or about April 6, 2025, indicating that its securities will be subject to immediate trading suspension and delisting action by Nasdaq.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is actively pursuing a business combination, the need for an extension and the potential for liquidation introduce uncertainty and risk.

Positives

• The extension provides additional time to complete the proposed business combination with Semnur Pharmaceuticals, Inc.
• Shareholders retain the right to redeem their shares if they do not approve of the extension or the subsequent business combination.
• The Sponsor is willing to invest additional capital to facilitate the extension.
• The company has already identified a potential target for a business combination.

Negatives

• If the extension is not approved, the company will be forced to liquidate, and warrants will expire worthless.
• Redemption of shares will reduce the net asset value and the amount held in the trust account.
• The company may need to obtain additional funds to complete an initial business combination.
• Nasdaq will suspend trading of the company's securities and commence delisting proceedings on or about April 6, 2025, due to the company's failure to consummate a business combination within 36 months of effectiveness of its initial public offering registration statement.

Risks

• There is no assurance that an initial business combination will be consummated even if the extension is approved.
• Redemptions may leave the company with insufficient cash to consummate a business combination.
• The Sponsor and company insiders may have conflicts of interest.
• A 1% U.S. federal excise tax may decrease the value of the company's securities following an initial business combination.
• Nasdaq will suspend trading of the company's securities and commence delisting proceedings on or about April 6, 2025, due to the company's failure to consummate a business combination within 36 months of effectiveness of its initial public offering registration statement.

Future Outlook

The company intends to continue seeking a business combination and will hold another shareholder meeting prior to the Extended Date to seek approval for an initial business combination.

Industry Context

This announcement is typical for SPACs approaching their deadline for completing a business combination, as they often seek extensions to finalize deals.

Comparison to Industry Standards

• Many SPACs seek extensions to complete business combinations, a common practice in the industry.
• The $0.02 per share per month contribution from the sponsor is a typical incentive to encourage shareholders to approve the extension.
• Comparable companies that have sought extensions include Fortune Rise Acquisition Corporation (Nasdaq: FRLA) and Feutune Light Acquisition Corporation (Nasdaq: FLFV).

Related Party Transactions

• The Sponsor will deposit $0.02 per public share per month into the trust account for up to eight months if the extension is approved.
• The Sponsor may loan the company up to $120,293.92 for the extension period.
• On August 30, 2024, the Sponsor and Scilex entered into a sponsor interest purchase agreement (the Sponsor Interest Purchase Agreement), pursuant to which Scilex purchased 500,000 Class B ordinary shares (the Purchased Interests), that were then-held by the Sponsor.

Stakeholder Impact

• Shareholders have the option to redeem their shares, potentially impacting the company's cash reserves.
• If the business combination is not completed, shareholders may lose their investment.
• Employees and other stakeholders of the target company may be affected by the outcome of the business combination.

Next Steps

• Shareholders will vote on the Extension Amendment Proposal and the Adjournment Proposal at the extraordinary general meeting on April 10, 2025.
• If the Extension Amendment Proposal is approved, the company will continue to seek a business combination until the Extended Date.
• The company intends to hold another shareholder meeting prior to the Extended Date in order to seek shareholder approval of an initial business combination.

Key Dates

Keywords

business combination, extension, redemption, SPAC, Denali Capital, Semnur, liquidation, trust account, sponsor, Nasdaq